Other Science

Syngenta Crop Protection and Valagro Withdraw from Potential SICIT Group transaction

Retail, Other Natural Resources, Agriculture, Other Science, Natural Resources, Science, Food, Beverage, Companies, AstraZeneca, ChemChina, Intensive farming, Novartis, Syngenta, Mergers and acquisitions, Seed companies, Agriculture

Friday, May 14, 2021 - 6:30am

Syngenta and Valagro continue to be impressed with the SICIT Group team, business and products.\nNonetheless, the latest circumstances have left it difficult for Syngenta and Valagro to develop a reasonable path forward for a transaction and, as a result, Syngenta and Valagro will not be proceeding with the proposed transaction.

Key Points:

Syngenta and Valagro continue to be impressed with the SICIT Group team, business and products.\nNonetheless, the latest circumstances have left it difficult for Syngenta and Valagro to develop a reasonable path forward for a transaction and, as a result, Syngenta and Valagro will not be proceeding with the proposed transaction.
We, of course, continue to wish the best success for SICIT Group and all associated with SICIT Group.\nSyngenta is one of the world\xe2\x80\x99s leading agriculture companies, comprised of Syngenta Crop Protection and Syngenta Seeds.
Syngenta Crop Protection and Syngenta Seeds are part of Syngenta Group.
Valagro became part of Syngenta Crop Protection in 2020.\nData protection is important to us.

Exicure Announces Appointment of Brian C. Bock as Chief Financial Officer (CFO)

Banking, Research, Other Health, General Health, Professional services, Pharmaceutical, Genetics, Science, Other Professional Services, Biotechnology, Finance, Health, Other Science, Spherical nucleic acid, SNA, XC2

Thursday, May 13, 2021 - 10:24pm

b'Exicure, Inc.\xc2\xae (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA\xe2\x84\xa2) technology, today announced the appointment of Brian C. Bock as the Company\xe2\x80\x99s Chief Financial Officer (CFO) effective immediately.\nThis press release features multimedia.

Key Points:

b'Exicure, Inc.\xc2\xae (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA\xe2\x84\xa2) technology, today announced the appointment of Brian C. Bock as the Company\xe2\x80\x99s Chief Financial Officer (CFO) effective immediately.\nThis press release features multimedia.
View the full release here: https://www.businesswire.com/news/home/20210513006058/en/\n\xe2\x80\x9cExicure\xe2\x80\x99s proprietary SNA platform technology holds great potential for treating unmet neurological and rare diseases.
I am pleased to be joining such a talented and dedicated team,\xe2\x80\x9d said Mr. Bock, CFO of Exicure.
Bock brings over 20 years of life science investment banking, mergers and acquisitions and partnering experience to the Company.

Hiring Surge Happening in Oregon’s Life Science and Biotech Sectors – Career Match Event to Link Seekers With Area’s Largest Industry Firms

Research, Medical devices, Human resources, Professional services, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Employment, Human resources, Oregon, United States, Administrative divisions

Thursday, May 13, 2021 - 10:01pm

b'The bioscience industry provides direct and indirect employment of 47,000 jobs in Oregon, showing substantial growth in the past decade.

Key Points:

b'The bioscience industry provides direct and indirect employment of 47,000 jobs in Oregon, showing substantial growth in the past decade.
Employers looking to hire can engage by contacting Julie Black at Oregon Bio, at julie@oregonbio.org .\nNoted Terry Smith, regional human resource executive, \xe2\x80\x9cThe industry is hiring as fast as it can.
Every bio company in Oregon that I know of is hiring, in some cases faster than even the highest-flying tech start-ups.
Between 2002-2017, total bioscience employment in Oregon jumped 72 percent among the five industry subsectors.

Aptinyx Reports First Quarter 2021 Financial Results and Highlights

Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Mental health, Other Science, Research, Science, Clinical trials, Administrative law, Criminal law, Discretion, Public administration, Articles, Law, Justice

Thursday, May 13, 2021 - 9:05pm

Any such consideration would be a matter for review at the FDA\xe2\x80\x99s discretion following the completion of the study.

Key Points:

Any such consideration would be a matter for review at the FDA\xe2\x80\x99s discretion following the completion of the study.
Aptinyx expects its current cash balance to support anticipated operations into 2023.\nCollaboration Revenue: Revenue was $1.0 million for the first quarter of 2021 compared to $0.8 million for same period in 2020.
ET to review its financial results and highlights for the first quarter of 2021 and subsequent period.
Aptinyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.\n'

PhaseBio Reports First-Quarter 2021 Financial Results and Recent Business Highlights

Science, Cardiology, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical trials, Microsoft, Software, Operating systems, Communication, Forward-looking statement, Private Securities Litigation Reform Act, LinkedIn, Twitter

Thursday, May 13, 2021 - 9:00pm

Additionally, the data demonstrated stability in functional status with no clinically-meaningful deterioration for two patients at two and six months after treatment.

Key Points:

Additionally, the data demonstrated stability in functional status with no clinically-meaningful deterioration for two patients at two and six months after treatment.
PhaseBio is eligible to receive up to an additional $30 million of funding if specific, pre-defined clinical development milestones for bentracimab are met.\nCash and cash equivalents at March 31, 2021 were $77.0 million, compared to $28.1 million at December 31, 2020.
For more information, please visit www.phasebio.com , and follow us on Twitter @PhaseBio and LinkedIn .\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements speak only as of the date hereof, and PhaseBio Pharmaceuticals, Inc. disclaims any obligation to update these statements except as may be required by law.\n"

TFF Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

Research, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Communication, Forward-looking statement

Thursday, May 13, 2021 - 9:00pm

b'TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the first quarter ended March 31, 2021, as well as provided a business update on recent corporate and clinical developments.

Key Points:

b'TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the first quarter ended March 31, 2021, as well as provided a business update on recent corporate and clinical developments.
Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially.
TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements.
TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.\n'

Applied DNA Second Fiscal Quarter 2021 Financial Results Feature 384% Year-Over-Year Growth in Revenues

Other Health, Research, Oncology, Infectious diseases, Hospitals, Genetics, Clinical trials, Science, Biotechnology, Stem cells, Other Science, Health, Communication, Forward-looking statement, GAAP, United States Generally Accepted Accounting Principles, Financial statements

Thursday, May 13, 2021 - 9:10pm

The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information presented in accordance with GAAP.

Key Points:

The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information presented in accordance with GAAP.
We use this non-GAAP financial measure for internal financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons of the performance and results of operations of our core business.
Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the performance of our business by excluding non-cash expenses that may not be indicative of our recurring operating results.
Forward-looking statements describe Applied DNA\xe2\x80\x99s future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA.

Maxar Technologies Announces Voting Results from Annual Meeting of Stockholders

Technology, Public relations, Investor relations, Communications, Telecommunications, Aerospace, Software, Manufacturing, Data management, Science, Other Science, Stock market, Financial markets, Maxar Technologies, Westminster, Colorado, Forward-looking statement, Exchange, Security, United States Securities Regulation

Thursday, May 13, 2021 - 9:05pm

Our unique approach combines decades of deep mission understanding and a proven commercial and defense foundation to deploy solutions and deliver insights with unrivaled speed, scale and cost effectiveness.

Key Points:

Our unique approach combines decades of deep mission understanding and a proven commercial and defense foundation to deploy solutions and deliver insights with unrivaled speed, scale and cost effectiveness.
Maxar\xe2\x80\x99s 4,400 team members in over 20 global locations are inspired to harness the potential of space to help our customers create a better world.
Maxar trades on the New York Stock Exchange and Toronto Stock Exchange as MAXR.
For more information, visit www.maxar.com .\nCertain statements and other information included in this release constitute "forward-looking information" or "forward-looking statements" (collectively, "forward-looking statements") under applicable securities laws.

Astrotech Reports Third Quarter of Fiscal Year 2021 Financial Results

Health, Security, Technology, Other Technology, Other Science, Science, Biotechnology, Communication, Forward-looking statement

Thursday, May 13, 2021 - 9:15pm

b'Astrotech Corporation (NASDAQ: ASTC) reported its financial results for the third quarter of fiscal year 2021, which ended March 31, 2021.\nDuring and subsequent to quarter end, we continued to strengthen our balance sheet for future growth by raising $50.1 million in total proceeds.

Key Points:

b'Astrotech Corporation (NASDAQ: ASTC) reported its financial results for the third quarter of fiscal year 2021, which ended March 31, 2021.\nDuring and subsequent to quarter end, we continued to strengthen our balance sheet for future growth by raising $50.1 million in total proceeds.
They have also agreed to manufacture AgLAB\xe2\x80\x99s AgLAB-1000 and BreathTech\xe2\x80\x99s BreathTest-1000 once those products are officially released.
For information, please visit www.astrotechcorp.com .\nThis press release contains information about our new products under development, the AgLAB-1000 and BreathTest-1000.
Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement.

Montrose Environmental Group to Attend Upcoming Investor Conferences

Professional services, Engineering, Environment, Manufacturing, Other Science, Finance, Science

Thursday, May 13, 2021 - 9:15pm

b'Montrose Environmental Group, Inc. (the \xe2\x80\x9cCompany,\xe2\x80\x9d \xe2\x80\x9cMontrose\xe2\x80\x9d or \xe2\x80\x9cMEG\xe2\x80\x9d) (NYSE: MEG) announced today that the Company will attend the following virtual investor conferences:\nNeedham 16th Annual Virtual Technology & Media Conference, May 17, 2021\nBofA Securities 2021 Virtual Transportation, Airlines, & Industrials Conference, May 19, 2021\nWilliam Blair 41st Annual Growth Stock Conference, June 1, 2021\nStifel 2021 Virtual Cross Sector Insight Conference, June 10, 2021\nMontrose is a leading environmental solutions company focused on supporting commercial and government organizations as they deal with the challenges of today, and prepare for what\xe2\x80\x99s coming tomorrow.

Key Points:

b'Montrose Environmental Group, Inc. (the \xe2\x80\x9cCompany,\xe2\x80\x9d \xe2\x80\x9cMontrose\xe2\x80\x9d or \xe2\x80\x9cMEG\xe2\x80\x9d) (NYSE: MEG) announced today that the Company will attend the following virtual investor conferences:\nNeedham 16th Annual Virtual Technology & Media Conference, May 17, 2021\nBofA Securities 2021 Virtual Transportation, Airlines, & Industrials Conference, May 19, 2021\nWilliam Blair 41st Annual Growth Stock Conference, June 1, 2021\nStifel 2021 Virtual Cross Sector Insight Conference, June 10, 2021\nMontrose is a leading environmental solutions company focused on supporting commercial and government organizations as they deal with the challenges of today, and prepare for what\xe2\x80\x99s coming tomorrow.
With more than 2,000 employees across over 70 locations around the world, Montrose combines deep local knowledge with an integrated approach to design, engineering, and operations, enabling the Company to respond effectively and efficiently to the unique requirements of each project.
From comprehensive air measurement and laboratory services to regulatory compliance, emergency response, permitting, engineering, and remediation, Montrose delivers innovative and practical solutions that keep its clients on top of their immediate needs \xe2\x80\x93 and well ahead of the strategic curve.
For more information, visit www.montrose-env.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210513005662/en/\n'